T. Rowe Price Associates
CRVS icon

T. Rowe Price Associates’s Corvus Pharmaceuticals CRVS Stock Holding History

T. Rowe Price Associates’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.6M Buy
3,789,126
+871,826
+30% +$12.1M 0.01% 857
2026
Q1 		$42.7M Buy
2,917,300
+2,883,195
+8,454% +$46M ﹤0.01% 822
2025
Q4 		$263K Buy
34,105
+1,696
+5% +$13.4K ﹤0.01% 2706
2025
Q3 		$239K Buy
32,409
+6,110
+23% +$31.3K ﹤0.01% 2715
2025
Q2 		$106K Buy
+26,299
New +$95.7K ﹤0.01% 2880
2020
Q1 		– Sell
-647,174
Closed -$3.52M – 2523
2019
Q4 		$3.52M Sell
647,174
-949,395
-59% -$3.32M ﹤0.01% 1464
2019
Q3 		$4.81M Sell
1,596,569
-165,679
-9% -$695K ﹤0.01% 1383
2019
Q2 		$6.59M Sell
1,762,248
-203,794
-10% -$798K ﹤0.01% 1367
2019
Q1 		$7.9M Sell
1,966,042
-20,121
-1% -$84.9K ﹤0.01% 1350
2018
Q4 		$7.29M Sell
1,986,163
-2,010
-0.1% -$13.7K ﹤0.01% 1354
2018
Q3 		$17.1M Sell
1,988,173
-11,926
-0.6% -$119K ﹤0.01% 1275
2018
Q2 		$22M Sell
2,000,099
-4,576
-0.2% -$51.1K ﹤0.01% 1172
2018
Q1 		$23.1M Buy
2,004,675
+1,698,459
+555% +$16.1M ﹤0.01% 1139
2017
Q4 		$3.17M Buy
306,216
+300
+0.1% +$3.84K ﹤0.01% 1490
2017
Q3 		$4.88M Sell
305,916
-38,685
-11% -$535K ﹤0.01% 1443
2017
Q2 		$4.17M Sell
344,601
-450,795
-57% -$4.81M ﹤0.01% 1434
2017
Q1 		$16.5M Buy
795,396
+182,819
+30% +$2.86M ﹤0.01% 1229
2016
Q4 		$8.76M Sell
612,577
-25,720
-4% -$391K ﹤0.01% 1341
2016
Q3 		$10.5M Buy
638,297
+3,409
+0.5% +$49.1K ﹤0.01% 1305
2016
Q2 		$8.8M Sell
634,888
-100
-0% -$1.35K ﹤0.01% 1313
2016
Q1 		$8.95M Buy
+634,988
New +$9.11M ﹤0.01% 1293

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates's CRVS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Corvus Pharmaceuticals (CRVS) stake by 30% in Q2 2026, buying an estimated $12.1M and bringing the position to 3,789,126 shares worth $56.6M. The position accounts for 0.01% of the portfolio, ranked #857.

T. Rowe Price Associates first reported a position in CRVS in Q1 2016 and has held it in 21 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • T. Rowe Price Associates held 3,789,126 shares of Corvus Pharmaceuticals worth $56.6M as of Q2 2026.
  • T. Rowe Price Associates bought 871,826 Corvus Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
  • Corvus Pharmaceuticals made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #857 holding.
  • T. Rowe Price Associates first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 21 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.